Multifunctional nanoparticles for use in theranostic applications
暂无分享,去创建一个
[1] G. Baldwin,et al. Gastrin-releasing peptide and cancer. , 2006, Biochimica et biophysica acta.
[2] Jan Grimm,et al. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles , 2006, Nature materials.
[3] T. Koji,et al. Doxorubicin‐induced DNA intercalation and scavenging by nuclear glutathione S‐transferase π , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[5] D. Discher,et al. Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.
[6] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[7] Ezequiel Bernabeu,et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.
[8] B. Liu,et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] C. Ehrhardt,et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] T. Park,et al. siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.
[11] H. Maeda,et al. The EPR Effect and Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century , 2005 .
[12] S. Bhatia,et al. Probing the Cytotoxicity Of Semiconductor Quantum Dots. , 2004, Nano letters.
[13] Domenico Coppola,et al. MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.
[14] L. Brannon-Peppas,et al. Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.
[15] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[16] D. Neri,et al. The use of phage display for the development of tumour targeting agents. , 2000, Advanced drug delivery reviews.
[17] M. Schwaiger,et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] Rongsheng E. Wang,et al. Development of NGR peptide-based agents for tumor imaging. , 2011, American journal of nuclear medicine and molecular imaging.
[19] Tina Hernandez-Boussard,et al. Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.
[20] P. Keegan,et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). , 2007, The oncologist.
[21] Mary E Napier,et al. More effective nanomedicines through particle design. , 2011, Small.
[22] Yasunori Fujita,et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.
[23] Subra Suresh,et al. Size‐Dependent Endocytosis of Nanoparticles , 2009, Advanced materials.
[24] H. Ueno,et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.
[25] H. Hong,et al. In Vivo Tumor Targeting and Drug Delivery with Mesoporous Silica Nanoparticles , 2013 .
[26] Kwangmeyung Kim,et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. , 2012, Biomaterials.
[27] Tejraj M Aminabhavi,et al. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[28] J. Bacri,et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. , 2003, Biomaterials.
[29] Jinho Park,et al. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.
[30] A. R. Kulkarni,et al. Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[31] Pedro M. Valencia,et al. Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .
[32] M J Hawkins,et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Efstathios Karathanasis,et al. Targeted nanotechnology for cancer imaging. , 2014, Advanced drug delivery reviews.
[34] C. Takimoto,et al. Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. , 2007 .
[35] Robert Langer,et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.
[36] Mark E. Davis. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.
[37] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[38] K. Kataoka,et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.
[39] Dong Soo Lee,et al. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. , 2011, Small.
[40] A. Jemal,et al. Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[41] R. Berges. Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability , 2005 .
[42] S. Sahoo,et al. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.
[43] Theresa M Reineke,et al. Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.
[44] E. Nagore,et al. Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome , 2000, American journal of clinical dermatology.
[45] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[46] Y. Matsumura. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. , 2011, Advanced drug delivery reviews.
[47] Philip S Low,et al. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.
[48] Y. Maitani,et al. Functional coating of liposomes using a folate– polymer conjugate to target folate receptors , 2012, International journal of nanomedicine.
[49] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .
[50] Igor L. Medintz,et al. Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.
[51] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[52] M. Kalia,et al. Personalized oncology: recent advances and future challenges. , 2013, Metabolism: clinical and experimental.
[53] C. Lok,et al. The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.
[54] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[55] Samir Mitragotri,et al. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[56] Norased Nasongkla,et al. Functionalized Micellar Systems for Cancer Targeted Drug Delivery , 2007, Pharmaceutical Research.
[57] Sarah Hitch,et al. THE CHRONOLOGY OF EARLY EPIC , 2014, The Classical Review.
[58] Seungpyo Hong,et al. The Binding Avidity of a Nanoparticle-based Multivalent Targeted Drug Delivery Platform , 2022 .
[59] Menachem Motiei,et al. Nanoparticles as computed tomography contrast agents: current status and future perspectives. , 2012, Nanomedicine.
[60] V. Muzykantov,et al. Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.
[61] Xianglong Hu,et al. Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. , 2012, Biomaterials.
[62] S S Gambhir,et al. Molecular imaging: current status and emerging strategies. , 2010, Clinical radiology.
[63] Pat Zanzonico,et al. Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems , 2012, Radiation research.
[64] Francesco Stellacci,et al. Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.
[65] D. Simberg,et al. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.
[66] Mingwu Shen,et al. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. , 2013, Biomaterials.
[67] S. Sahoo,et al. Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.
[68] Gaurav Sahay,et al. Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[69] Indu Bala,et al. PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.
[70] H. Shan,et al. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma , 2012, International journal of nanomedicine.
[71] É. Boisselier,et al. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. , 2010, Chemical reviews.
[72] P. Low,et al. Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.
[73] T. Yen,et al. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery. , 2011, Biomaterials.
[74] S. Sahoo,et al. Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.
[75] A. Bjourson,et al. Diagnostic, Prognostic and Theranostic Genetic Biomarkers for Rheumatoid Arthritis , 2013 .
[76] D. Tien,et al. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. , 2013, Bioorganic & medicinal chemistry letters.
[77] C. Fraser,et al. Development and preclinical evaluation of SEL-068, a novel targeted Synthetic Vaccine Particle (tSVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine (75.11) , 2012, The Journal of Immunology.
[78] Ying Liu,et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. , 2011, Small.
[79] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[80] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[81] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[82] Xue-Long Sun,et al. Chemically-selective surface glyco-functionalization of liposomes through Staudinger ligation. , 2009, Chemical communications.
[83] R. Tsien,et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.
[84] Mingwu Shen,et al. Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. , 2014, Biomaterials.
[85] R. Roesler,et al. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] Stan W. Casteel,et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity , 2010, Proceedings of the National Academy of Sciences.
[87] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[88] Shan Jiang,et al. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.
[89] J. Arias,et al. Drug targeting strategies in cancer treatment: an overview. , 2011, Mini reviews in medicinal chemistry.
[90] Kostas Kostarelos,et al. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. , 2011, Accounts of chemical research.
[91] Donghoon Lee,et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. , 2005, Nano letters.
[92] P. Choyke,et al. Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.
[93] Y. Jeong,et al. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. , 2010, ACS nano.
[94] Z. Fayad,et al. Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots , 2008, Angiogenesis.
[95] P. Nygren,et al. Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.
[96] Marilena Loizidou,et al. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.
[97] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[98] M Ferrari,et al. Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[99] Beom Suk Lee,et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. , 2012, Biomaterials.
[100] Gert Storm,et al. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.
[101] Stephanie E. A. Gratton,et al. The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.
[102] Antonina Rait,et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[103] Xiaoyuan Chen,et al. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[104] Tae-You Kim,et al. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.
[105] E. Moase,et al. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer , 2008, Journal of drug targeting.
[106] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[107] R. Schiffelers,et al. ICS-283: a system for targeted intravenous delivery of siRNA , 2006, Expert opinion on drug delivery.
[108] Probal Banerjee,et al. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. , 2010, Biomaterials.
[109] H. Maeda. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[110] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[111] V. Torchilin,et al. Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.
[112] L. Kaminskas,et al. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. , 2011, Nanomedicine.
[113] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[114] Jonathan D. Ashley,et al. Ligand-targeted liposome design: challenges and fundamental considerations. , 2014, Trends in biotechnology.
[115] D. Kerr,et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.
[116] Craig J Hawker,et al. Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. , 2013, Bioconjugate chemistry.
[117] Hongzhe Sun,et al. Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.
[118] S. Ferrari,et al. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma , 2007, Anti-cancer drugs.
[119] A. S. Moses,et al. Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.
[120] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[121] Michael J Welch,et al. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.
[122] B. Cheson,et al. Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.
[123] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[124] A. M. Rush,et al. X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. , 2011, Angewandte Chemie.
[125] G. Hsiue,et al. Multifunctional Micelles for Cancer Cell Targeting, Distribution Imaging, and Anticancer Drug Delivery , 2007 .
[126] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[127] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[128] G. Calin,et al. Non‐coding RNAs as theranostics in human cancers , 2012, Journal of cellular biochemistry.
[129] Kerry K. Karukstis,et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.
[130] S. Nie,et al. Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .
[131] Nicholas J Long,et al. 'Two is better than one'--probes for dual-modality molecular imaging. , 2009, Chemical communications.
[132] I. Kwon,et al. Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[133] J. Minna,et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. , 2010, Molecular pharmaceutics.
[134] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[135] R. Niu,et al. Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. , 2012, International journal of pharmaceutics.
[136] K. Landfester,et al. Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. , 2008, Macromolecular bioscience.
[137] Francesco M Veronese,et al. PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.
[138] Jean-Pierre Benoit,et al. Parameters influencing the stealthiness of colloidal drug delivery systems. , 2006, Biomaterials.
[139] Clara L Santos-Cuevas,et al. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. , 2011, Bioconjugate chemistry.
[140] Y. Bae,et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. , 2014, Biomaterials.
[141] Kazuo Maruyama,et al. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.
[142] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[143] D. Peer,et al. Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.
[144] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[145] S. Swanson,et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement , 2008, International journal of nanomedicine.
[146] Kangseok Lee,et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. , 2011, Journal of biotechnology.
[147] D. Faulds,et al. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.
[148] Gil Y. Melmed,et al. Certolizumab pegol , 2022, Nature Reviews Drug Discovery.
[149] Horst Kessler,et al. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .
[150] Y. Shimada,et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[151] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .
[152] M. Ross,et al. Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations , 1994 .
[153] E. Olson,et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. , 2010, Cancer cell.
[154] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[155] Subhra Mohapatra,et al. Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Co-delivery of Drugs, Genes and MRI Contrast Agents. , 2013, Journal of materials chemistry. B.
[156] Srikanth K. Iyer,et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.
[157] Cao Xie,et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[158] Werner Jaschke,et al. Molecular imaging with nanoparticles: giant roles for dwarf actors , 2008, Histochemistry and Cell Biology.
[159] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[160] Horst Kessler,et al. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. , 2003, Biomaterials.
[161] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[162] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[163] Lehui Lu,et al. Nanoparticulate X-ray computed tomography contrast agents: from design validation to in vivo applications. , 2012, Accounts of chemical research.
[164] R. J. Lee,et al. Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.
[165] A. Boddy,et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.
[166] S. Wise. Nanocarriers as an emerging platform for cancer therapy , 2007 .